|
|
|
|
|
by friendzis
337 days ago
|
|
https://pubmed.ncbi.nlm.nih.gov/38629387/ > Conclusion: Semaglutide displays potential for weight loss primarily through fat mass reduction. However, concerns arise from notable reductions in lean mass, especially in trials with a larger number of patients. That's a significant long-term damage to health, quite possibly permanent for 40+ patients. |
|
Intermittent/time-restricted fasting
https://jamanetwork.com/journals/jamainternalmedicine/fullar...?
That's simply how the body reacts to a caloric deficit, without additional exercise. If you combine both IFT and resistance exercise, you find no muscle loss at all:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7468742/
That's an apple to oranges comparison, because there's nothing preventing someone from taking Ozempic from exercising on the side.
And in fact, other trials found that the overall ratio of fat:muscle lost was rather favorable, and that functional strength wasn't compromised:
https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.157...
>Based on contemporary evidence with the addition of magnetic resonance imaging-based studies, skeletal muscle changes with GLP-1RA treatments appear to be adaptive: *reductions in muscle volume seem to be commensurate with what is expected given ageing, disease status, and weight loss achieved, and the improvement in insulin sensitivity and muscle fat infiltration likely contributes to an adaptive process with improved muscle quality, lowering the probability for loss in strength and function*
Interpreting the risks and benefits of medication isn't a trivial exercise, if you're driven by a handful of studies or ignorant of the wider context, then it's easy to be mislead.